Author + information
- Received May 4, 2020
- Revision received May 27, 2020
- Accepted May 27, 2020
- Published online June 23, 2020.
- Ersilia M. DeFilippis, MDa,∗∗ (, )@ersied727,
- Nosheen Reza, MDb,∗,
- Elena Donald, MDa,
- Michael M. Givertz, MDc,
- JoAnn Lindenfeld, MDd and
- Mariell Jessup, MDe
- aDivision of Cardiology, Columbia University Irving Medical Center, New York, New York
- bDivision of Cardiology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
- cDivision of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- dVanderbilt Heart and Vascular Institute, Nashville, Tennessee
- eAmerican Heart Association, Dallas, Texas
- ↵∗Address for correspondence:
Dr. Ersilia M. DeFilippis, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 622 West 168th Street, New York, New York 10032.
• Patients with HF may be at increased risk for severe disease and complications from COVID-19.
• COVID-19 infection can cause or worsen HF through a variety of mechanisms.
• Delivery of HF care has been significantly restructured during the COVID-19 pandemic.
• Future studies should address the impact of pandemic delays on outcomes in patients with HF.
The coronavirus-2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF) who have contracted COVID-19 as well as those without COVID-19 who have been impacted by the restructuring of health care delivery. Patients with HF and other cardiovascular comorbidities are at risk for severe disease and complications of infection. Similarly, COVID-19 has been demonstrated to cause myocarditis and may be implicated in new-onset cardiomyopathy. During this pandemic, special considerations are needed for patients with advanced HF, including those supported by durable left ventricular assist devices (LVADs) and heart transplant recipients. The purpose of this review is to summarize emerging data regarding the development of HF secondary to COVID-19 infection in patients with advanced HF and the implications of the pandemic for care of uninfected patients with HF.
↵∗ Drs. DeFilippis and Reza contributed equally to this manuscript as co-first authors.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.
- Received May 4, 2020.
- Revision received May 27, 2020.
- Accepted May 27, 2020.
- 2020 American College of Cardiology Foundation